1-8 of 8
Felix Bachmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P238: Derazantinib, an inhibitor of fibroblast growth factor receptors 1-3, synergises with paclitaxel in pre-clinical gastric tumor models

Paul M. McSheehy, Mahmoud El Shemerly, Felix Bachmann, Laurenz Kellenberger, Heidi Lane
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P238.
https://doi.org/10.1158/1535-7163.TARG-21-P238
Published: 01 December 2021
View articletitled, Abstract P238: Derazantinib, an inhibitor of fibroblast growth factor receptors 1-3, synergises with paclitaxel in pre-clinical gastric tumor models
Journal Articles

Abstract C096: Modeling the clinical paradigm of lisavanbulin (BAL101553) deployment in patient-derived xenografts (PDX) of glioblastoma (GBM)

Danielle M Burgenske, Ann C Mladek, Jenny L Pokorny, Heidi A Lane, Felix Bachmann, Rachael A Vaubel, Mark A Schroeder, Katrina K Bakken, Lihong He, Zeng Hu, Brett L Carlson, Surabhi Talele, Gautham Gampa, Matthew L Kosel, Paul A Decker, Jeanette E Eckel-Passow, William F Elmquist, Jann Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C096.
https://doi.org/10.1158/1535-7163.TARG-19-C096
Published: 01 December 2019
View articletitled, Abstract C096: Modeling the clinical paradigm of lisavanbulin (BAL101553) deployment in patient-derived xenografts (PDX) of glioblastoma (GBM)
Journal Articles

Abstract LB-C12: Derazantinib (DZB): A dual FGFR/CSF1R-inhibitor active in PDX-models of urothelial cancer

Paul McSheehy, Felix Bachmann, Nicole Forster-Gross, Marc Lecoultre, Mahmoud El Shemerly, Mila Roceri, Stefan Reinelt, Laurenz Kellenberger, Paul R Walker, Heidi Lane
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): LB-C12.
https://doi.org/10.1158/1535-7163.TARG-19-LB-C12
Published: 01 December 2019
View articletitled, Abstract LB-C12: Derazantinib (DZB): A dual FGFR/CSF1R-inhibitor active in PDX-models of urothelial cancer
Journal Articles

The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells

Raphaël Bergès, Aurélie Tchoghandjian, Stéphane Honoré, Marie-Anne Estève, Dominique Figarella-Branger, Felix Bachmann, Heidi A. Lane, Diane Braguer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (11): 2740–2749.
https://doi.org/10.1158/1535-7163.MCT-16-0252
Published: 01 November 2016
View articletitled, The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells
Open the PDF for The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells in another window
Includes: Supplementary data
Journal Articles

Abstract A183: The novel tubulin-binding ‘tumor checkpoint controller’ BAL101553 exerts EB1 expression-dependent antitumor effects on glioblastoma stem-like cells in vitro and in vivo

Raphael Berges, Aurélie Tchoghandjian, Stephane Honore, Dominique Figarella-Branger, Felix Bachmann, Heidi Lane, Diane Braguer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A183.
https://doi.org/10.1158/1535-7163.TARG-15-A183
Published: 01 December 2015
View articletitled, Abstract A183: The novel tubulin-binding ‘tumor checkpoint controller’ BAL101553 exerts EB1 expression-dependent antitumor effects on glioblastoma stem-like cells in vitro and in vivo
Journal Articles

Abstract C29: Elevated CDKN1A (p21) expression in human cancer cell variants selected for resistance to the novel microtubule depolymerizing agent BAL27862 (active moiety of BAL101553).

George E. Duran, Heidi Lane, Felix Bachmann, Branimir I. Sikic
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C29.
https://doi.org/10.1158/1535-7163.TARG-11-C29
Published: 12 November 2011
View articletitled, Abstract C29: Elevated CDKN1A (p21) expression in human cancer cell variants selected for resistance to the novel microtubule depolymerizing agent BAL27862 (active moiety of BAL101553).
Journal Articles

Abstract C233: BAL27862: A unique microtubule‐targeted agent with a potential for the treatment of human brain tumors

Anne Schmitt‐Hoffmann, Dominique Klauer, Klaus Gebhardt, Pascal Fullhardt, Alain Brendle, Patrick Hardgreaves, Caroline Schlaefle, Christian Bucher, Jochen Spickermann, Rosalie Defoin, Karin Burger, Van Vuong, Felix Bachmann, Martin Pruschy, Heidi Lane
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C233.
https://doi.org/10.1158/1535-7163.TARG-09-C233
Published: 10 December 2009
View articletitled, Abstract C233: BAL27862: A unique microtubule‐targeted agent with a potential for the treatment of human brain tumors
Journal Articles

Abstract C229: BAL27862: A novel anticancer agent which dissociates microtubules and creates a distinct cellular phenotype

Felix Bachmann, Karin Burger, Jens Pohlmann, Laurenz Kellenberger, Heidi Lane
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C229.
https://doi.org/10.1158/1535-7163.TARG-09-C229
Published: 10 December 2009
View articletitled, Abstract C229: BAL27862: A novel anticancer agent which dissociates microtubules and creates a distinct cellular phenotype